Johnson & Johnson (NYSE:JNJ) reported third-quarter 2026 earnings and revenue above Wall Street expectations on Tuesday, supported by growth in its Innovative Medicine business and continued expansion across its medical technology operations.
The US healthcare company posted adjusted earnings per share of $2.59, exceeding the analyst consensus of $2.53 by $0.06. Revenue increased 5.9% year on year to $25.4 billion, compared with $24.0 billion in the corresponding quarter of 2025 and slightly ahead of market expectations of $25.38 billion.
Following the results, Johnson & Johnson raised its full-year 2026 financial guidance, forecasting adjusted earnings per share of $11.05 to $11.15 and revenue of between $101.0 billion and $101.4 billion.
The company’s shares advanced 0.1% following the announcement.
Johnson & Johnson generated revenue of $25.4 billion during the third quarter, representing an increase of 5.9% from the previous year.
The result exceeded the analyst consensus forecast of $25.38 billion by approximately $20 million.
Adjusted earnings per share reached $2.59, beating expectations by $0.06.
The quarterly performance reflected growth across both of the company’s principal operating divisions, Innovative Medicine and MedTech.
Innovative Medicine remained the larger contributor to revenue, supported by demand for several established pharmaceutical products.
Meanwhile, MedTech recorded growth in cardiovascular technologies, including electrophysiology products and Shockwave.
The combined performance prompted management to increase its financial expectations for the remainder of 2026.
Johnson & Johnson’s Innovative Medicine division reported third-quarter sales of $16.8 billion, up 7.7% compared with the same period last year.
Growth was supported by strong performance from several medicines across the company’s pharmaceutical portfolio.
The company highlighted TREMFYA, DARZALEX, CARVYKTI and TECVAYLI as important contributors.
TREMFYA is used in the treatment of certain immune-mediated inflammatory conditions, while DARZALEX, CARVYKTI and TECVAYLI are therapies used in the treatment of multiple myeloma, a form of blood cancer.
The performance of these products helped drive the division’s year-on-year revenue increase.
Innovative Medicine accounted for approximately two-thirds of Johnson & Johnson’s total quarterly sales, making it the principal contributor to the company’s growth.
The company did not provide individual sales figures for the highlighted medicines in the supplied announcement.
Johnson & Johnson’s MedTech division generated sales of $8.6 billion during the third quarter, representing growth of 2.5% year on year.
The company identified its cardiovascular business as an important source of growth, particularly electrophysiology products and Shockwave technology.
Electrophysiology products are used in procedures involving the diagnosis and treatment of abnormal heart rhythms.
Shockwave technology is associated with intravascular lithotripsy, a technique used to treat calcified arteries during certain cardiovascular procedures.
The expansion of these businesses supported MedTech revenue growth, although the division increased sales at a slower rate than Innovative Medicine.
Johnson & Johnson did not disclose additional financial details for the individual cardiovascular product categories in the information provided.
Johnson & Johnson reported US sales of $15.0 billion, representing an increase of 9.1% compared with the previous year.
International revenue rose 1.5% to $10.4 billion.
The figures indicate that the US market was the stronger contributor to the company’s geographical revenue growth during the quarter.
Domestic sales represented approximately 59% of total revenue, while international operations accounted for the remaining 41%.
The difference in growth rates highlights the importance of the US market to Johnson & Johnson’s overall financial performance.
The company did not provide a detailed regional breakdown of international sales in the supplied results.
Following its third-quarter performance, Johnson & Johnson increased its financial outlook for fiscal 2026.
The company now expects adjusted earnings per share of between $11.05 and $11.15.
The midpoint of the range, $11.10, is slightly above the analyst consensus estimate of $11.08.
Johnson & Johnson also raised its full-year revenue guidance to between $101.0 billion and $101.4 billion.
The midpoint of the new revenue range is $101.2 billion, compared with the market consensus of $101.4 billion.
While the updated guidance represents an increase in management’s expectations, the revenue range remains at or below the cited consensus forecast.
The revised outlook reflects the company’s confidence in the performance of its pharmaceutical and medical technology businesses during the remainder of the year.
Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, attributed the quarterly performance to the company’s portfolio and improving growth momentum.
“Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” Duato said.
The comments followed revenue growth in both Innovative Medicine and MedTech, alongside a stronger performance in the US market.
The company continues to operate across pharmaceuticals and medical technology, with its portfolio including treatments for complex diseases and devices used in surgical and cardiovascular procedures.
The latest results indicate that pharmaceutical sales remain the main source of revenue growth, supported by expansion in selected MedTech categories.
Johnson & Johnson’s third-quarter results showed revenue and adjusted earnings ahead of market expectations, accompanied by an increase in full-year guidance.
Innovative Medicine sales rose 7.7% to $16.8 billion, while MedTech revenue increased 2.5% to $8.6 billion.
US sales advanced 9.1%, outperforming the 1.5% growth recorded internationally.
The company now expects full-year adjusted earnings per share of $11.05 to $11.15 and revenue of $101.0 billion to $101.4 billion.
For investors, the performance of key pharmaceutical products, cardiovascular technologies and the US market will remain important factors in assessing the company’s progress.
Although Johnson & Johnson raised its financial outlook, the updated revenue midpoint remains below the cited analyst consensus, providing an additional point of comparison as the company approaches the end of fiscal 2026.
Johnson & Johnson stock price
| 10 hours | |
| 12 hours | |
| Oct-16 | |
| Oct-16 | |
| Oct-16 | |
| Oct-16 | |
| Oct-16 | |
| Oct-16 | |
| Oct-15 | |
| Oct-15 | |
| Oct-15 | |
| Oct-15 | |
| Oct-15 | |
| Oct-15 | |
| Oct-14 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite